Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 10/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335103 | 0.86 | NOS2 (0.42) | NOS2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL6328362 | 0.83 | CYP2D6 (0.47) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6337819 | 0.81 | NOS2 (0.67) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6328345 | 0.80 | NOS2 (0.65) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6337105 | 0.80 | NOS2 (0.56) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6330637 | 0.80 | NOS2 (0.56) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6327580 | 0.80 | NOS2 (0.47) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL6332201 | 0.79 | NOS2 (0.66) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6329874 | 0.79 | NOS2 (0.48) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6332391 | 0.78 | NOS2 (0.50) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900243-B2 | Phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-05-31 | — | — | US | disclosed |
| EP-1263715-B1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030065174-A1 | Novel phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-04-03 | — | — | US | disclosed |
| EP-1263715-A1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062714-A1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065174-A1 | Novel phenylheteroalkylamine derivatives | OPRK1, NOS2, OPRM1 | NOS2 2/4885CYP2D6 59/4885SLC6A2 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.